APR-246

5:31
The role of venetoclax in older patients with AML
Andrew Wei
3:14
APR-246 with azacitidine for p53 mutated MDS and AML
Thomas Cluzeau
1:53
Immuno-oncology paving the way in MDS
Uma Borate
0:52
Azacitidine in the treatment of MDS
David Steensma
1:32
Novel drug targets for MDS
Stephen Nimer
1:38
APR-246 and azacitidine in TP53m MDS and AML
Thomas Cluzeau
3:03
Mutant p53 re-activator APR-246 in MDS/AML
David Sallman
1:22
MDS updates from ASH 2019
David Steensma
1:45
What’s to come for MDS therapy?
David Sallman
3:33
Targeting BCL-2 in older AML: novel venetoclax combinations
Andrew Wei
3:24
Data for APR-246 and azacitidine in patients with mTP53 MDS and AML
David Sallman
1:56
Promising approaches and clinical trials in MDS
David Steensma
1:06
Is there hope for treating TP53-mutated MDS?
Mark Levis
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals